<DOC>
	<DOCNO>NCT02211079</DOCNO>
	<brief_summary>The purpose study assess effect single multiple daily dose 50 milligram ( mg ) JNJ-54861911 pharmacokinetics ( PK ) ( study way drug enters leave blood tissue time ) caffeine , midazolam , tolbutamide healthy male participant .</brief_summary>
	<brief_title>A Study Assess Effect JNJ-54861911 Pharmacokinetics Cocktail Representatives Cytochrome P450 ( CYP ) 3A4 , CYP2B6 , CYP2C9 , CYP1A2 Substrates</brief_title>
	<detailed_description>This single-center , open-label ( participant researcher aware treatment , participant receive ) , fixed-sequence study healthy male participant . The study consist 3 phase : Screening Phase ( within 21 2 day prior first dose administration Day 1 ) , Open Label Treatment Phase ( Day 1 Day 9 ) , Follow-up Phase ( 7 14 day discharge study unit Day 10 early withdrawal ) . The maximum duration study 7 week per participant . During Open-Label Treatment Phase , participant receive JNJ-54861911 , 50 mg ( 2*25 mg tablet ) orally daily Day 2 Day 9 along caffeine 100 mg ( 2*50 mg tablet ) , midazolam 2 mg ( 1 milliliter [ mL ] , 2 mg/mL solution ) , tolbutamide 500 mg tablet , orally Day 1 , 2 , 9 . Blood sample collect pre-dose ( Day 1 ) Day 10 understand PK characteristic midazolam , 1-hydroxy midazolam ( midazolam metabolite ) , caffeine , paraxanthine ( caffeine metabolite ) , tolbutamide , 4-hydroxytolbutamide carboxytolbutamide ( tolbutamide metabolite ) . In addition , blood sample collect Day -1 enrol participant study genetic factor may influence PK , safety , and/or tolerability JNJ-54861911 co-medications . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Tolbutamide</mesh_term>
	<criteria>Signed informed consent document indicate understand purpose procedure require study , willing participate study Body mass index 18 30 kilogram per square meter Must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform Screening admission ( Day 1 predose ) Man , sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate Investigator , must also agree donate sperm study 90 day receive last dose study drug Participant must healthy basis clinical laboratory test perform Screening per Investigator 's judgment History current liver renal insufficiency , closedangle glaucoma , significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , dermatological metabolic disturbance Known allergy , hypersensitivity , intolerance JNJ54861911 excipients , sulfonamide , midazolam , caffeine tolbutamide . History human immunodeficiency virus ( HIV ) antibody positive , test positive HIV Screening History drug alcohol abuse accord current Diagnostic Statistical Manual Mental Disorders ( DSM ) criterion within 6 month Screening positive test result ( ) alcohol and/or drug abuse ( include barbiturate , opiate , cocaine , cannabinoids , amphetamine , metamphetamines , benzodiazepine cotinine ) Screening admission Smoking cigarette ( equivalent ) and/or use nicotine base product within 3 month prior study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-54861911</keyword>
	<keyword>Caffeine</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Tolbutamide</keyword>
	<keyword>Cytochrome P450 3A4</keyword>
	<keyword>Cytochrome P450 2C9</keyword>
	<keyword>Cytochrome P450 1A2</keyword>
	<keyword>Alzheimer 's disease</keyword>
</DOC>